Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 60 Neoplasms 59 Lung Neoplasms 32 Prostatic Neoplasms 24 Colorectal Neoplasms 24 Carcinoma, Non-Small-Cell Lung 21 Neoplastic Cells, Circulating 20 Head and Neck Neoplasms 19 Pancreatic Neoplasms 17 Melanoma 14 Ovarian Neoplasms 13 Carcinoma, Hepatocellular 12 Esophageal Neoplasms 10 Colonic Neoplasms 10 Uterine Cervical Neoplasms 9 Liver Neoplasms 9 Glioma 9 Squamous Cell Carcinoma of Head and Neck 8 Multiple Myeloma 8 Leukemia, Myeloid, Acute 8 Sarcoma 7 Neoplasm Metastasis 7 Endometrial Neoplasms 7 Stomach Neoplasms 6 Neoplasm, Residual 6 Myeloproliferative Disorders 6 Leukemia 6 Kidney Neoplasms 6 Gastrointestinal Neoplasms 6 Carcinoma, Renal Cell 6

Interventions

pyrotinib 4 neratinib 2 tucatinib 1 trastuzumab deruxtecan 1 pertuzumab 1 Trastuzumab 1 Hospital Information Systems 1 Genetic Testing 1 Electronic Health Records 1 Blood Specimen Collection 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × HER2-positive Breast Cancer × Blood Specimen Collection × Clear all

NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡